Cited by 12Receptor Mechanisms and SignalingComputational Drug Discovery MethodsNeuropeptides and Animal Physiology

A Putative Binding Model of Nitazene Derivatives at the μ-Opioid Receptor

Open access
Clayton, Joseph, Shi, Lei, Robertson, Michael J., Skiniotis, Georgios, Michaelides, Michael, Stavitskaya, Lidiya, Shen, Jana·2025·Neuropharmacology

Abstract

. Our computational analysis provides new insights into the mechanism of μOR-opioid recognition, paving the way for investigations of the structure-activity relationships of nitazenes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2025.110437

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nitazenes may carry cardiotoxic potential; computational analyses predict a high probability of hERG potassium channel inhibition, raising concerns about proarrhythmic effects.

    “In addition, nitazenes may carry cardiotoxic potential; computational analyses predict a high probability of hERG potassium channel inhibition, raising concerns about proarrhythmic effects [38,39,40].”

    From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [39]

    The Introduction reports that metonitazene overdose was associated with cardiac arrest at a higher rate than overdoses involving other substances, lending limited support to concern about cardiac harm. But the paper’s computational analyses concern μ-opioid-receptor binding; our copy does not report a prediction of hERG inhibition or proarrhythmic effects. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • It is possible to predict emerging nitazene analogues using advances in forensic intelligence and artificial intelligence tools.

    “Nowadays, with advances in forensic intelligence and artificial intelligence tools, it is possible to predict emerging nitazene analogues, as demonstrated in recent studies [30,39]”

    From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [39]

    The Abstract and Results and Discussion describe computational predictions of receptor-binding poses for eight specified nitazenes, not predictions of which analogues will emerge. The Introduction notes nitazenes already found on the illicit market, but the passages do not address using forensic intelligence or artificial intelligence to anticipate emerging analogues (searched those terms and predictive analogues). (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Clayton, J., Shi, L., Robertson, M. J., Skiniotis, G., Michaelides, M., Stavitskaya, L., & Shen, J.
Affiliations
  • University of Maryland, Baltimore (US)
  • United States Department of Health and Human Services (US)
  • Stanford Medicine (US)
  • National Institute on Drug Abuse (US)
  • United States Food and Drug Administration (US)
Corresponding author
  • Stavitskaya, Lidiya
  • Shen, Jana
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2025-08
Volume
273
Pages
110437
ISSN
0028-3908 (ISSN-L)
OpenAlex
W4409176997
Cited by
12
References
51
Citations by year
2026: 8 · 2025: 4
FWCI
3.61
Type
journal article
Language
en
Open access
Locations
  • Neuropharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders
  • National Institute on Drug Abuse
  • U.S. Food and Drug Administration
  • NIH National Institute of General Medical Sciences (R35GM148261)
  • Oak Ridge Institute for Science and Education
  • National Institutes of Health
  • U.S. Department of Energy
  • NIH National Cancer Institute (R01CA256557)
  • Intramural Research Program (Z1A-DA000606 \u2217, Z1A-DA000069)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
mu-opioid receptor, structure-activity relationship, opioid analgesics
MeSH terms
Analgesics, Opioid, Binding Sites, Humans, Protein Binding, Receptors, Opioid, mu, Molecular Dynamics Simulation, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review